Plain-English translation of NCT05006430 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing PRIM-DJ2727, a capsule treatment made from healthy gut bacteria collected from screened donors. The idea is that restoring good bacteria in your gut may help reduce liver damage and inflammation in people with severe alcoholic hepatitis. Half of participants will receive the medication along with standard care, and half will receive a placebo (inactive capsule) along with standard care.
Heavy drinking damages the gut barrier and allows harmful bacteria to leak into the bloodstream, which can make liver disease worse. Current treatments like steroids don't always work well and can cause side effects. This trial is exploring whether restoring healthy gut bacteria might help the body fight liver damage more effectively.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll receive either the medication or a placebo capsule along with your regular medical care for alcoholic hepatitis. You'll take one capsule daily for one week, then once weekly for three more weeks (10 doses total). The study will monitor your liver function, gut bacteria changes, and overall safety throughout the trial period.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States